Diabetic macular oedema

In the RESTORE extension study, Prof Paolo Lanzetta from the Department of Ophthalmology, University of Udine introduced results from 240 patients with diabetic macular oedema (DME) who received individualised treatment with ranibizumab in a regimen consistent with the European Union label, the standard of care in wet AMD. The data presented at the 12th EURETINA Congress in Milan, Italy, showed that patients who were originally treated with ranibizumab received an average of 13.9 injections over three years. The mean of seven letters of visual acuity gained in the RESTORE core study were maintained with an average of 3.7 injections in the second year and 2.7 in the third year.Â
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.